An observational study in Axial Spondylarthritis (axSpA) and Psoriatic Arthritis (PsA), sponsored by Adelphi Real World. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Adelphi Real World · Observational
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.
Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the study period.
579 studies on the registry are indexed under Arthritis, Psoriatic; 132 are open to participants now.
This study's planned enrollment of 700 is above the median of 300 across 235 observational studies indexed under Arthritis, Psoriatic.
Browse Arthritis, Psoriatic studies →This is the only study on the registry with Adelphi Real World as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Participants will be selected from patients attending NHS hospitals and related healthcare sites targeted across the United Kingdom, including England, Scotland, Wales, and Northern Ireland. These sites are secondary and tertiary care centres where patients with axial spondyloarthritis or psoriatic arthritis are routinely managed by rheumatology services.
Exclusion Criteria:
-Participation in a clinical trial at enrolment.
Patients diagnosed with axial spondyloarthritis (axSpA) who are initiating treatment with bimekizumab, upadacitinib, or a tumour necrosis factor-alpha inhibitor.
Other: observational study
Patients diagnosed with psoriatic arthritis (PsA) who are initiating treatment with bimekizumab, upadacitinib, risankizumab, guselkumab or a tumour necrosis factor-alpha inhibitor.
Other: observational study
This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.
Number of participants that have achieved Low Disease Activity (LDA) at 12 months.
Time frame: At 12 months
Number of participants that have achieved Minimal Disease Activity (MDA) at 12 months.
Time frame: At 12 months
Change from baseline in PROM scores at 12 months.
Time frame: At 12 months
Plan to share: No — Individual participant data (IPD) from this study will not be shared with other researchers. In accordance with the study protocol and relevant data protection regulations, including GDPR, only aggregated data and summary results will be made available for scientific dissemination. All data provided will be fully anonymized and presented in aggregate form to ensure participant confidentiality and privacy. No individual-level data or information that could identify participants will be shared outside of the authorized study team.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.